Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

FDA approves Accord’s BLA for trastuzumab, biosimilar to Genentech’s Herceptin®

Apr 5, 2023

Accord BioPharma, the US speciality division of Intas, announced that the FDA has accepted its BLA for proposed trastuzumab biosimilar HLX02 for adjuvant treatment of HER2-overexpressing breast cancer, HER2-overexpressing metastatic breast cancer, and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.  HLX02 was originally developed by Accord’s business partner Shanghai Henlius Biotech, Inc.  In 2021, Henlius granted Accord the exclusive rights to develop and commercialise HLX02 in North America.

Separately, on 15 February 2023 Henlius announced the FDA acceptance of Henlius’ BLA for HLX02.  It is unclear whether this is the same BLA as that which Accord has recently announced.